Noted by hotlips on the Discussion thread, Bloomberg highlight the additional advantages (below) to BioProgress in forming this strategic alliance with Inyx, announced yesterday. Clearly, the Tabwrap machine, sited in Manchester, will be a 'full-blown' system (as confirmed by RT to jan-mar) and capable of being contracted out 'commercially' to between 2 and 4 pharmas requiring blockbuster products each year.
“Inyx and BioProgress Form Strategic Collaboration
NEW YORK, Dec. 21 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board: IYXI), a specialty pharmaceutical company focused on niche drug-delivery technologies and products, announced today that its wholly owned, United Kingdom-based subsidiary, Inyx Pharma Limited, has entered into a strategic collaboration with BioProgress plc (Nasdaq and AIM: BPRG), an innovative specialty pharma and healthcare company with U.K. headquarters in Cambridge, England.
Under the collaboration, Inyx will provide assistance to broadly commercialize BioProgress' TABWRAP(TM) technology. TABWRAP(TM) is a patented, high-speed continuous process for delivering tablets or caplets in an ingestible or edible film sheet. It is applicable to a broad range of product applications, including prescription and over-the-counter pharmaceuticals.
Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are pleased that BioProgress has selected to team up with Inyx to assist in the validation requirements and commercialization of its TABWRAP(TM) technology. We look forward to a growing collaboration with BioProgress."
Richard Trevillion, Chief Executive Officer of BioProgress, said, "Inyx has a long history of assisting companies and innovative pharmaceutical technologies with the required regulatory approvals on production processes and controls. We are confident that BioProgress will be able to accelerate its own development plan during 2007 through this strategic alliance with Inyx……….."
Full Article:
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
